|
Market Closed -
Nasdaq
23:00:00 30/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.890 USD | +2.72% |
|
-0.53% | -84.50% |
| 09-21 | Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to S&P Global BMI Index | CI |
| 08-31 | Guggenheim Downgrades Tenax Therapeutics to Neutral From Buy | MT |
Company Valuation: Tenax Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 26.21 | 4.979 | 6.553 | 218.5 | 494.6 | 105.4 | - | - |
| Change | - | -81.01% | 31.6% | 3,233.86% | 126.39% | -78.69% | - | - |
| Enterprise Value (EV) 1 | 26.21 | 4.979 | 6.553 | 218.5 | 494.6 | -237.2 | 95.2 | 105.4 |
| Change | - | -81.01% | 31.6% | 3,233.86% | 126.39% | -147.96% | 140.13% | 10.71% |
| P/E | -0.66x | -0.3x | -0.71x | -5.38x | -9.1x | -1.27x | -1.23x | -1.14x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0.1x | -0.6x | -0.15x | -0.37x | -0.16x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 8.78x |
| EV / Revenue | - | - | - | - | - | - | - | 8.78x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0.8x | -0.45x | -0.8x | -11.2x | -8.77x | 3.12x | -1.09x | -1x |
| EV / FCF | - | - | - | - | - | 4.74x | -0.95x | -0.66x |
| FCF Yield | - | - | - | - | - | 21.1% | -105% | -151% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2,528 | -600.8 | -31.04 | -1.15 | -1.34 | -1.452 | -1.5 | -1.608 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 12 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -32.73 | -11.05 | -8.234 | -19.49 | -56.38 | -75.97 | -87.2 | -104.9 |
| Net income 1 | -32.47 | -11.05 | -7.711 | -17.6 | -52.6 | -72.73 | -84.06 | -99.54 |
| Net Debt 1 | - | - | - | - | - | -342.6 | -10.2 | - |
| Reference price 2 | 1,664.000 | 178.238 | 21.968 | 6.190 | 12.190 | 1.840 | 1.840 | 1.840 |
| Nbr of stocks (in thousands) | 15.8 | 27.9 | 298 | 35,292 | 40,570 | 57,282 | - | - |
| Announcement Date | 3/29/22 A | 3/31/23 A | 3/28/24 A | 3/25/25 A | 3/10/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.27x | - | - | - | 105M | |
| 20.87x | 7.45x | 14.96x | 1.42% | 71.53B | |
| 31.24x | 9x | 28.05x | 0.04% | 60.12B | |
| 34.13x | 6.11x | 18.31x | 0.95% | 48.85B | |
| 34.64x | 3.34x | 14.41x | -.--% | 44.28B | |
| -21.08x | 228.26x | -22.72x | -.--% | 43.83B | |
| 47.85x | 5.53x | 30.37x | -.--% | 41.53B | |
| 27.07x | 7.8x | 20.09x | 0.42% | 30.13B | |
| 32.39x | 6.91x | 17.94x | -.--% | 27.98B | |
| -70.94x | 13.62x | -69.42x | -.--% | 25.25B | |
| Average | 13.49x | 32.00x | 5.78x | 0.32% | 39.36B | |
| Weighted average by Cap. | 19.22x | 31.83x | 9.93x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TENX Stock
- Valuation Tenax Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
